Abstract: The invention is directed to methods and kits that allow for classification of malignant melanoma cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

Abstract: The invention is directed to methods and kits that allow for classification of colorectal cancer cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

Abstract: The present invention relates to algorithms for use in defining genomic subgroups of tumors and cancer cell lines. The present invention also relates to methods for assembling panels of tumors and cancer cell lines according to genomic subgroups for use in testing the efficacy of one or more pharmaceutical compounds in the treatment of subjects suffering from at least one cancer.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: Provided is a liquid crystal (LC) device and method thereof. The device comprises (i) a body of liquid crystal, (ii) a first layer comprising a first material, and (iii) a second layer comprising a second material; wherein the first layer is located between the body of liquid crystal and the second layer; the first layer alone aligns the liquid crystal in a first orientation; the second layer alone aligns the liquid crystal in a second orientation; and the first orientation is different from the second orientation. With optimized first layer thickness, the invention can be used in sensor applications to improve detection sensitivity, and in LCD applications with enhanced control over LC pretilt transition.

Abstract: An exemplary key includes a main body and a filling portion. The main body is made of ceramic material. The main body defines a through hole therein. The filling portion fills the through hole. The filling portion is capable of allowing light passing through the filling portion.

Abstract: A method for implementing charging communication services is provided, wherein, the charging system includes a charging module and an expression analyzer; the charging module first determines a plurality of basic expression factors, and a user configures expressions based on the expression factors; the charging module reads a communication record, obtains the values of the expression factors by analyzing the communication record, and transmits the values of the expression factors to the expression analyzer; the expression analyzer performs the expression operation assigned with the expression factor values and finally returns the operation result to a charging module; and the charging module searches the corresponding charging rate according to the operation result and calculate the fee.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: A detector apparatus is disclosed that includes a housing and a multilayer disposed within the housing. The multilayer defining a leading edge and a trailing edge and is adapted to interact with a plurality of high-energy photons, impingent from the leading edge, to permit passage of photons of at least one selected energy. The multilayer is secured to a first securement adjacent to the leading edge. The multilayer is secured to a second securement bracket adjacent to the trailing edge. At least one detector is disposed adjacent to the trailing edge of the multilayer to detect the impingent high-energy photons. An adjustment mechanism operatively connects to the second securement bracket to adjust the position of the second securement bracket, thereby altering an angular position of the multilayer.

Abstract: The present invention comprises a fusion molecule comprising a Fc? fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CH?2-CH?3-CH?4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1 heavy chain (?hinge-CH?2-CH-?3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

Abstract: There is a working fluid for a heating and cooling. The fluid is a blend of from about 1% to about 98% by weight 1,1,1,2,3,3,3-heptafluoropropane, from about 1% to about 98% by weight 1,1,1,3,3,3-hexafluoropropane, and from about 1% to about 98% by weight 1,1,1,2-tetrafluoroethane. The 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,3,3,3-hexafluoropropane, and 1,1,1,2-tetrafluoroethane are from about 90% or more by weight of the blend. There are also an apparatus that uses the blend and methods for heating and cooling using the blend.

Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Abstract: The present invention comprises a fusion molecule comprising a Fc? fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CH?2-CH?3-CH?4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1 heavy chain (?hinge-CH?2-CH?3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Abstract: A detector apparatus is disclosed that includes a housing and a multilayer disposed within the housing. The multilayer defining a leading edge and a trailing edge and is adapted to interact with a plurality of high-energy photons, impingent from the leading edge, to permit passage of photons of at least one selected energy. The multilayer is secured to a first securement adjacent to the leading edge. The multilayer is secured to a second securement bracket adjacent to the trailing edge. At least one detector is disposed adjacent to the trailing edge of the multilayer to detect the impingent high-energy photons. An adjustment mechanism operatively connects to the second securement bracket to adjust the position of the second securement bracket, thereby altering an angular position of the multilayer.

Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Abstract: A method for implementing charging communication services is provided, wherein, the charging system includes a charging module and an expression analyzer; the charging module first determines a plurality of basic expression factors, and a user configures expressions based on the expression factors; the charging module reads a communication record, obtains the values of the expression factors by analyzing the communication record, and transmits the values of the expression factors to the expression analyzer; the expression analyzer performs the expression operation assigned with the expression factor values and finally returns the operation result to a charging module; and the charging module searches the corresponding charging rate according to the operation result and calculate the fee.

Abstract: The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and Fc?RI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

Abstract: A flexible circuit incorporating an electrostatic discharge limiting feature, comprising a dielectric substrate selected from polyimide or liquid crystal polymer film having at least one conductive trace coated on at least one surface of the substrate wherein the discharge limiting feature includes a thin conductive polymer coating selectively applied over a at least a portion of the non-critical region of the circuit, said feature reducing the surface resistivity of the circuit to about 104 ohms to about 108 ohms and having tribocharging of less than about 50 V.